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Nanometre-sized vesicles, also known as exosomes, are derived from endosomes of diverse cell types and present in multiple
biological fluids. Depending on their cellular origins, the membrane-bound exosomes packed a variety of functional proteins
and RNA species. These microvesicles are secreted into the extracellular space to facilitate intercellular communication. Collective
findings demonstrated that exosomes fromHIV-infected subjects sharemany commonalitieswithHuman ImmunodeficiencyVirus
Type I (HIV-1) particles in terms of proteomics and lipid profiles. These observations postulated that HIV-resembled exosomes
may contribute to HIV pathogenesis. Interestingly, recent reports illustrated that exosomes from body fluids could inhibit HIV
infection, which then bring up a new paradigm for HIV/AIDS therapy. Accumulative findings suggested that the cellular origin of
exosomes may define their effects towards HIV-1. This review summarizes the two distinctive roles of exosomes in regulating HIV
pathogenesis. We also highlighted several additional factors that govern the exosomal functions. Deeper understanding on how
exosomes promote or abate HIV infection can significantly contribute to the development of new and potent antiviral therapeutic
strategy and vaccine designs.
1. Introduction
The membrane-bound exosomes are present in a wide range
of human fluids such as urine [1], plasma [2], saliva [3], ascites
[4], breast milk [5], semen [6], bronchoalveolar lavage liquid
[7], amniotic fluid [8], and cerebrospinal fluid [9]. These
microvesicles are secreted from various types of immune cells
such as dendritic cells (DCs) [10], macrophages [11], T cells
[12], and B cells [13], as well as tumor cells from various
cancers [14, 15]. Exosomes are mainly responsible for cell-cell
communication processes such as cell proliferation [15], cell
invasion [16], and immune and gene regulation [17, 18]. It is
known that exosomes are derived from cellular endosomes,
where the inward budding takes place on the endosomal
multivesicular bodies (MVBs) to form the intraluminal
vesicles (ILVs) [19]. The subsequent molecular mechanism
then determines the fate of ILVs, entering the lysosomal
degradation pathway or released extracellularly as exosomes
upon fusion of MVB membrane with the plasma membrane
[20].
Accumulative findings have demonstrated that exosomes
highly resembled HIV particles in many aspects, from their
physical properties to composition [21–24]. This has given
rise to two models that explain these similarities [24]. First,
the Trojan exosome hypothesis proposed that retroviruses are
originated from exosomes following the evolution involving
gag gene mutation [25]. This explained the ability of virus
to exploit the preexisting exosome biogenesis pathway for
viral dissemination and be able to infect cells in Env- and
receptor-independent manner [26, 27]. The second model,
however, is not in line with the evolutionary theory of
the virus. Instead, the “crosstalk” or “hijacker” hypothesis
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suggested that the retroviruses have evolved to hijack the
intercellular communication pathway of the host to promote
HIV pathogenesis [28]. Although both models differ from
each other, the similarity of the compositions (i.e., lipids, pro-
teins, carbohydrates, and RNAs) between viral particles and
exosomes suggests that exosomes may play an indispensable
role in HIV pathogenesis.
Recently, several reports have demonstrated that exo-
somes contain internal cargoes that can inhibit HIV infec-
tion and replication [29–31]. These antiviral exosomes were
mostly found in the body fluids such as semen and breast
milk. However, the inhibitory action of exosomes is not
well described compared to its viral infection enhancement
effects. This may be due to the high abundance of HIV
pathogenesis promoting molecules within the composition
of exosomes, which may mask the existing antiviral effects,
if any. By far, collective findings have shown that exosomes
can either promote or inhibit HIV infection, with little
understanding upon the critical factors and/or the exact
mechanisms that determine the exosomal effects in viral
infection. In general, the source (i.e., from different cell types
and biological fluids) and the composition of exosomes may
exert the decisive role in contribution to HIV/AIDS patho-
genesis. More effort is required to thoroughly understand
the exosomal function in HIV infection in order to benefit
the development of new-era HIV/AIDS therapy and vaccine
designs.
2. Morphological and Biological Properties
of Exosomes and HIV Particles
Exosomes share several common structural and molecular
properties with HIV. Physically, their size and density range
from 50 to 150 nm in diameter [32] and 1.13 to 1.21 g/mL [33],
respectively, and both are surrounded by a lipid bilayer. In
addition to morphological similarities, they possess similar
composition such as lipids (i.e., cholesterol and glycosphin-
golipids) [13], carbohydrates (i.e., highmannose and complex
N-linked glycans) [34], proteins (i.e., tetraspanins, MHC
molecules, actin, and TSG101) [35, 36], and RNA species [24].
Exosomes from HIV-infected cells are also enriched with
viral proteins such as Nef [37] and viral RNAs [18, 38]. Due
to these similarities, HIV-1 is believed to be generated by
the same pathway of exosome biogenesis [24, 39]. Moreover,
a substantial amount of the host component (e.g., MHC-
II) can enter the viral particles [25]. This can be one of the
mechanisms that is exploited by viruses to evade the host
immune surveillance.
Despite sharing most of the biochemical features, HIV
particles have a few principal differences in comparison with
exosomes. First, HIV has more organized and uniform struc-
tures regardless of the type of infected cells while the structure
of exosomal vesicles varies depending on the parental cell
after the membrane budding [40]. Second, the exosomal
contents are highly diverse from different sources while the
biochemical content of HIV virions is steadily consistent.
These differences allow the purification methods based on
iodixanol density gradients and immunoaffinity isolation to
efficiently harvest exosome-free HIV virions [40, 41].
3. Distinct Functions of Exosomes
from Different Sources
The composition of exosomes derived from biological fluids
is highly variable from one to the other, which suggest the
composition may define the distinct effects of exosomes
(either promoting or inhibiting viral pathogenesis). Cumu-
lative evidence suggested that the exosomal effect on HIV
mainly depends on their cellular origins [42]. In most cases
but not all, exosomes derived from HIV-infected cells are
more virulent and enhance infection, while exosomes from
uninfected cells have protective properties. In this section,
we discuss the exosomal functions and their effects on HIV
pathogenesis based on their sources or origins (summarized
in Table 1).
3.1. Blood/Plasma/Serum. Human blood is where the HIV
virions reside and is the main biofluid responsible for
HIV transmission. The blood also contains various types
of cells of both HIV-susceptible and uninfected cells that
secrete exosomes. It has been postulated that HIV hijacks
the exosome biogenesis pathway which carries various viral
proteins and RNAs for viral dissemination process [24].
A general review on how exosomes enhance the spread
of various infections has been recently reported [23, 42].
Exosomes secreted from HIV-infected cells had been found
to contain chemokine receptors, CCR5 andCXCR4, that were
delivered to recipient cells to facilitate HIV establishment
and spreading [43, 44]. Exosomes from HIV-1 infected
macrophages had also been known to facilitate viral transfer
to uninfected cells [45]. Exosomes that contain HIV Nef
protein have multiple pathogenic effects such as induction
of T-cell apoptosis [37], inhibition of RNA interference [46],
and downmodulation of cell surface molecules (i.e., MHC-I
and CD4) for immune evasion [47]. Nef protein also induces
exosomal secretion [37], thereby contributing to HIV/AIDS
pathogenesis. Unlike the transfer of CCR5 and/or CXCR4
which primarily direct HIV infection, Nef proteins promote
HIV infection by activating the uninfected cells.
Other viral components that are usually found in exo-
somes are HIV Gag [39], viral mRNA/miRNA [18], and
pathogen-associated RNAs such as HIV trans-activation
response (TAR) RNA [48] that could enhance the viral
infection and replication in the recipient cells. Various host
surface molecules (CD45, CD86, and MHC-II) have also
been exported from HIV-infected cells via exosomes to
silence the immune response [49]. Additionally, exosomes
derived from infected dendritic cells (DCs) have a profound
enhancing effect on CD4+ T cell infection [50]. More
recently, Nef-induced exosome-associated ADAM17 (ADAM
metallopeptidase domain 17) had rendered resting CD4+ T
cells permissive to HIV-1 infection [51], whereas ADAM17
along with TNF-𝛼 has been known to synergistically activate
the latent HIV-1 in primary CD4+ T lymphocytes and
macrophages [52]. HIV particles are known to incorporate
Advances in Virology 3
Table 1: Dual effects of body fluids-derived exosomes against HIV infection.
Viral/antiviral effect Exosomal source Active component Reference
Promote HIV infection Blood/plasma/serum
CCR5 and CXCR4 [43, 44]




CD45, CD86, and MHC-II [49]
ADAM17, TNF-𝛼 [51, 52]
Undefined (from DCs) [50]
Inhibit HIV infection
Blood/plasma/serum




Tumor necrosis factor (TNF-𝛼) [61, 65]
Interleukins [61, 62]




IgA and IgG antibodies [68]
Mucin 1 (MUC-1) [69]
Oligosaccharides [70]
Undefined [31]
Semen Mucin 6 [72]
Undefined [30, 71]









various host cell components that enable the viruses to evade
the immune system.The exchange of these components could
be facilitated by the existing exosomes that are enriched with
the host components.While extensive studies have been con-
ducted on exosomes derived from HIV-infected cells, little is
known of the role of exosomes derived from uninfected cells
in viral pathogenesis. The increased exosomal secretion may
have increased the susceptibility of uninfected cells to HIV;
this however warrants future investigation.
Although exosomes are mainly enriched with viral com-
ponents that promote HIV/AIDS pathogenesis, a few reports
have shown that exosomes may potentially inhibit HIV
infection. APOBEC3G, a host cellular protein, has been
known to transfer from cell to cell through exosomes to
protect the recipient cell from HIV infection [29, 53, 54].
APOBEC3G, themost prominentmember of APOBEC3 (A3)
proteins, is a cellular cytidine deaminase that restricts HIV
replication by both DNA-editing and editing-independent
activities [55, 56]. In order to function, the APOBEC3G
must be incorporated into the virions [57]. The extensive
role of APOBEC3G in antiviral immunity has been recently
reviewed [58].The restrictive effect ismore prominent inVif -
deficient HIV-1 than the wild-type strain as the Vif proteins
target and counteract APOBEC3G for polyubiquitination
and degradation by the 26S proteasome [29]. APOBEC3G
proteins have been detected in human mammary tissues
and were packaged intomilk-borne virions and subsequently
restricted HIV-1 infectivity [53]. Besides, it has also been
shown that APOBEC3G inhibited viral replication by block-
ing the function of HIV-1 reverse transcriptase [54].
Although T lymphocytes are the primary reservoir of
HIV infection, exosomes released from T lymphocytes had
been found to have inhibitory effects against HIV. When
compared to CD4-depleted exosomes from CD4+ T cells,
CD4-containing exosomes efficiently inhibited HIV-1 infec-
tion [59]. This may be due to the masking of HIV-1 enve-
lope proteins by the exosomal CD4 that has subsequently
blocked HIV infection. Similarly, exosomes secreted from
CD8+ T cells were able to suppress HIV transcription
within the infected cells [60]. Other components from
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exosomes that inhibit viral infections are interleukins [61,
62], interferon-alpha [63], interferon-beta [64], and tumor
necrosis factor (TNF-𝛼) [61, 65].
3.2. Breast Milk. While exosome’s dual-functions were seen
in the blood-derived exosomes, current findings on milk-
derived exosomes are skewed towards their antiviral effects,
probably due to its role in providing natural passive immunity
for infants. Exosomes were found to contain several compo-
nents such as Lewis X [66], bile lipase [67], antibodies [68],
mucin 1 (MUC-1) [69], and oligosaccharides [70] that inhibit
theDC-mediatedHIV transmission to CD4+T lymphocytes.
More recently, the antiviral effect of exosomes has been
shown to be specifically derived from the milk since no
HIV-1 inhibition was seen in plasma-derived exosomes when
experimented in parallel [31]. In this study, themilk exosomes
bound to monocyte-derived dendritic cells (MDDCs) and
inhibited HIV-1 infection of MDDCs and the subsequent
viral transfer to CD4+ T cells. Cumulative work showed
that milk exosomes have a strong inhibitory effect; these
protective effects may be transferred to the uninfected cells
of newborns via breastfeeding as part of the passive antiviral
immunity. This may also be a reason why the HIV-1 trans-
mission via breastfeeding is rare. More efforts are currently in
progress to evaluate the potential of utilizing milk exosomes
in the antiviral therapy [42].
3.3. Semen. HIV-1 infection is notoriously known to be
transmitted through sexual intercourse. Surprisingly, the
semen-derived exosomes mainly possess antiviral effects
compared tomediatingHIV infection. It has been shown that
exosomes purified from healthy individuals inhibit the HIV-
1 replication in various cell types by blocking the postentry
viral RNA reverse transcription [30]. The same group has
also shown that exosomes in human semen were able to
restrict the HIV transmission in vivo in LP-BM5-infected
mice model [71]. Another group has also reported that the
mucin-containing exosomes were able to prevent the HIV-1
transfer from DCs to CD4+ T cells [72]. Similar to the milk
exosomes, these exosomes may presumably be transferred
from one to another to exert the antiviral or protective effects.
Yet, this seems to be inefficient as the number of HIV cases
due to sexual transmission increases every year. Although
several reports have highlighted the protective role of semen-
derived exosomes, the exact mechanism that is involved is
still unknown.This is important in order to control or prevent
the HIV spreading, particularly through unprotected sexual
intercourse.
3.4. Urine, Saliva, Ascites, and Other Biological Fluids. While
the anti-HIV action of exosomes has been shown in human
blood, semen, and breast milk, its antiviral potential in other
sources such as saliva and ascites is yet to be determined.
Since the composition of exosomes is heterogenous depend-
ing on the origins, it is of crucial importance to understand
the factors that may eventually lead to its viral or antiviral
effects. More efforts need to be done to reveal the activity of
exosomes and the mechanisms in these biofluids as they may
serve as an important source for antiviral therapies.
4. Decisive Factors for Exosome Functions
in HIV Infection
It is interesting that the exosome nanovesicles packed with
a very complex composition displayed two contradictory
functions towards HIV infection (Table 1). However, little
is known about the criteria that drive the ultimate role of
exosomes in HIV/AIDS pathogenesis. Cumulative findings
have demonstrated that the function of exosomes is mainly
directed by their cellular origin and composition. Exosomes
derived from HIV-infected T cells, monocyte/macrophage,
and dendritic cells contain several components that abate
viral infection [21, 24, 45]. These immune cells may release
immune-regulatory factors that possess antiviral property
such as interferon-alpha (IFN-𝛼) [63], interferon-beta (IFN-
𝛽) [64], tumor necrosis factor-alpha (TNF-𝛼) [65, 66], inter-
leukins (ILs) [66, 67], and APOBEG3G [29, 53, 54], which are
exported by exosomes from the cells. However, this antiviral
implication might be masked due to the lytic replication of
HIV that resulted in the pathogenic effects. To note, some
of the viral molecules such as Nef and viral TAR RNA have
been detected in exosomes which may further enhance the
infection [37, 48]. Similarly, the antiviral activity of exosomes
has been found in biological fluids (i.e., semen and breast
milk) that are rich in immunological molecules [30, 31]. This
indicates that the function of exosomes partly depends on
the cellular origin. However, the exact components and their
underlyingmechanism that contributes to the antiviral action
are left to be discovered.
In addition to the cellular origin of exosomes, the target or
recipient cells inwhich exosomes are delivered also play a piv-
otal role in viral pathogenesis. Exosomes are known to trans-
port fromHIV-infected CD4+ T cells among themselves [51]
as well as to other recipients cells such as dendritic cells and
macrophages [45, 73]. The dendritic cells were also known
to capture exosomes from the exosome-producer cells or
infected CD4+ T cells and export to HIV-susceptible cells for
the infection.These processes were termed as trans-infection
and trans-dissemination, respectively [73, 74]. During the
process, viral proteins such as chemokine receptors and Nef
may be delivered to the recipient cells, thereby enhancing
HIV infection and replication. Indeed, the ultimate functions
of exosomes in the HIV-infected individuals largely rely on
the composition of the nanosized exosomes. When both
surface molecules and internal cargoes of exosome have net
pathogenic effects, there is more likelihood that exosomes
would contribute to viral pathogenesis and vice versa. The
components of exosomes may also alter the intracellular sig-
nalling pathways [75, 76], thereby affecting HIV-1 infection.
It is well-known that the content of exosomes largely
varies depending on their origins. However, it is intriguing
that exosomes derived from the same source (i.e., blood-
derived exosomes) have opposing effects in HIV patho-
genesis. While individual components within the exosomes
appear to have opposing effects on HIV pathogenesis, the
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net effect of the exosomes may depend on the relative
strength of the effects. In addition to the net pathogenic
effect of exosomal contents, it is noteworthy that variation
in testing conditions such as culture conditions, exosome
or virions preparation, cell infection status, and exosomal
transfer or delivery status may also play role in determining
the outcome of exosomes in viral infection. For example,
the profile of exosomes generated in vitro from cultured
cells may differ drastically from exosomes that are freshly
harvested from biofluids. The variation of exosomes derived
from tumor cells cultured in vitro and in vivo had been
previously reported [77]. In this case, the experiments uti-
lizing exosomes prepared in vitro may not represent the in
vivo exosomal effects on viral infection. Second, the different
methods used in exosome or virions preparation may also
complicate the data interpretation. Exosomes prepared in
vitro might be contaminated with HIV virions during the
purification, thereby affecting the outcome of exosomes on
viral pathogenesis. Third, the efficiency of exosomal transfer
from the exosome producer cells to the recipient cells may
also play a key role in viral pathogenesis. For instance,
exosomes derived from cultured cells in vitro may not be as
potent in the exchange of exosomal contents (i.e., virulence
factors and/or antiviral components) as compared with in
vivo transfer [42]. Moreover, the level of exosome secretion
is dependent on the HIV infection status as Nef proteins
mediate the exosome release [37]. All of these factors have to
be taken into consideration by researchers before concluding
the study outcome.
5. Development of a New-Era
HIV Therapeutic Strategy
Cumulative findings demonstrate that the cell-encoded exo-
some pathways enhanceHIV infection, supported by the Tro-
jan exosome hypotheses [25] and the envelope protein- and
receptor-independent viral dissemination without involving
fusion events [26].On the other hand, exosomes derived from
the breast milk and semen exhibit modest antiviral effects
[30, 31]. Both of these contradictory functions of exosomes
pose a major impact to the existing strategy of anti-HIV drug
development and urge the discovery of new-era therapeutics.
For instance, the Env-targeting therapeutics may contribute
to a low extent or none at all to the exosome-mediated infec-
tion that can take place without Env-receptor fusion. Hence,
a more comprehensive strategy is needed to control the
infection. The exosomal pathway in which HIV was hijacked
for the viral dissemination can be targeted by newly designed
inhibitors to target exosome biogenesis and exosome uptake
in both Env-dependent and independent infections. Potential
exosomal targets are cellular enzymes (RNases, proteases, and
lipase), cytoplasmic proteins (TSG101, cyclophilins, MHC-II,
and tetraspanins), and HIV-related proteins (e.g., Nef, CCR5,
and CXCR4) [21, 23]. However, the specificity of the therapy
must be monitored as the host-derived exosomes may trigger
deleterious side effects. Several reports have shown that
exosomal inhibitors have reduced the overall Env-dependent
infection [30, 31] and these suggest the applicability of
inclusion of exosome inhibitors in the adjunctive HIV ther-
apy. Exosomes that exhibit antiviral activity can be purified
from the particular sources and developed into a potential
therapy. Indeed, more promising action is envisioned when
the exact components andmechanisms are revealed. It would
also be interesting to determine whether the relative amount
of HIV promoting versus HIV inhibiting exosomes could
affect disease progression and thereby serve as potential
biomarkers for prognosis. While this review focuses on the
role of exosomes in HIV infection, these nanovesicles have
also been shown to contribute to pathogenesis of other
viral classes such as Hepatitis B and C virus [21, 78] and
Herpes Simplex virus (HSV) [22]. Continuous efforts must
be made to enhance the understanding of the exosomal
function in these viral infections and their potential use in
the development of antiviral therapies.
6. Conclusions
To summarize, the host-derived exosomes enhance HIV
infection by several routes, including intercellular dissem-
ination of viral components and immune evasion whereas
only a limited number of reports have shown the antiviral
function of exosomes. Numerous factors, such as the cellular
origins, recipient cells, and the intracellular signalling that are
affected by exosomes, are currently thought to contribute to
the final outcome of exosome in the infection. Variation in
exosome preparation and testing conditionsmay significantly
affect the outcome of exosomes. Compared to other fields, the
exosomal functions inHIV and other types of viral infections
are apparently underexplored. More research is anticipated
to improve the understanding of the association between
exosomes and viral infections in order to reveal the potential
of exosomes in the development of anti-HIV therapy.
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